Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2
- PMID: 19073841
- DOI: 10.1096/fj.08-120857
Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2
Abstract
The hormone relaxin inhibits renal myofibroblast differentiation by interfering with TGF-beta1/Smad2 signaling. However, the pathways involved in the relaxin-TGF-beta1/Smad2 interaction remain unknown. This study investigated the signaling mechanisms by which human gene-2 (H2) relaxin regulates myofibroblast differentiation in vitro by examining its effects on mixed populations of fibroblasts and myofibroblasts propagated from injured rat kidneys. Cultures containing approximately 60-70% myofibroblasts were used to determine which relaxin receptors, G-proteins, and signaling pathways were involved in the H2 relaxin-mediated regulation of alpha-smooth muscle actin (alpha-SMA; a marker of myofibroblast differentiation). H2 relaxin only inhibited alpha-SMA immunostaining and collagen concentration in the presence of relaxin family peptide receptor 1 (RXFP1). H2 relaxin also induced a transient rise in cAMP in the presence of G(i/o) inhibition, and a sustained increase in extracellular signal-regulated kinase (ERK)-1/2 phosphorylation. Furthermore, inhibition of neuronal nitric oxide synthase (nNOS), NO, and cGMP significantly blocked the inhibitory effects of relaxin on alpha-SMA and Smad2 phosphorylation, while the NO inhibitor, L-nitroarginine methyl ester (hydrochloride) (L-NAME) significantly blocked the inhibitory actions of relaxin on collagen concentration in vivo. These findings suggest that relaxin signals through RXFP1, and a nNOS-NO-cGMP-dependent pathway to inhibit Smad2 phosphorylation and interfere with TGF-beta1-mediated renal myofibroblast differentiation and collagen production.
Similar articles
-
Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS.PLoS One. 2012;7(8):e42714. doi: 10.1371/journal.pone.0042714. Epub 2012 Aug 22. PLoS One. 2012. PMID: 22936987 Free PMC article.
-
The anti-fibrotic actions of relaxin are mediated through AT2 R-associated protein phosphatases via RXFP1-AT2 R functional crosstalk in human cardiac myofibroblasts.FASEB J. 2020 Jun;34(6):8217-8233. doi: 10.1096/fj.201902506R. Epub 2020 Apr 16. FASEB J. 2020. PMID: 32297670
-
H3 relaxin demonstrates antifibrotic properties via the RXFP1 receptor.Biochemistry. 2011 Mar 1;50(8):1368-75. doi: 10.1021/bi1013968. Epub 2011 Jan 31. Biochemistry. 2011. PMID: 21229994
-
Investigations into the inhibitory effects of relaxin on renal myofibroblast differentiation.Ann N Y Acad Sci. 2009 Apr;1160:294-9. doi: 10.1111/j.1749-6632.2008.03823.x. Ann N Y Acad Sci. 2009. PMID: 19416207 Review.
-
Site-related Effects of Relaxin in the Gastrointestinal Tract Through Nitric Oxide Signalling: An Updated Report.Curr Protein Pept Sci. 2017;18(12):1254-1262. doi: 10.2174/1389203718666170612104719. Curr Protein Pept Sci. 2017. PMID: 28606038 Review.
Cited by
-
Expression of RXFP1 Is Decreased in Idiopathic Pulmonary Fibrosis. Implications for Relaxin-based Therapies.Am J Respir Crit Care Med. 2016 Dec 1;194(11):1392-1402. doi: 10.1164/rccm.201509-1865OC. Am J Respir Crit Care Med. 2016. PMID: 27310652 Free PMC article.
-
Regional Diversities in Fibrogenesis Weighed as a Key Determinant for Atrial Arrhythmogenesis.Biomedicines. 2021 Dec 14;9(12):1900. doi: 10.3390/biomedicines9121900. Biomedicines. 2021. PMID: 34944715 Free PMC article. Review.
-
The Anti-fibrotic Actions of Relaxin Are Mediated Through a NO-sGC-cGMP-Dependent Pathway in Renal Myofibroblasts In Vitro and Enhanced by the NO Donor, Diethylamine NONOate.Front Pharmacol. 2016 Mar 31;7:91. doi: 10.3389/fphar.2016.00091. eCollection 2016. Front Pharmacol. 2016. PMID: 27065874 Free PMC article.
-
Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection.Eur Heart J Cardiovasc Pharmacother. 2016 Apr;2(2):119-30. doi: 10.1093/ehjcvp/pvv046. Epub 2015 Nov 26. Eur Heart J Cardiovasc Pharmacother. 2016. PMID: 27418970 Free PMC article. Review.
-
Circulating Relaxin-1 Level Is a Surrogate Marker of Myocardial Fibrosis in HFrEF.Front Physiol. 2019 Jun 4;10:690. doi: 10.3389/fphys.2019.00690. eCollection 2019. Front Physiol. 2019. PMID: 31231242 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous